SEC Form 4 · accession 0000919574-18-004518
Lineage Cell Therapeutics, Inc. · LCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neal C Bradsher
Director · 10% Owner
Period of report
Jul 1, 2018
Accepted (ET)
Jul 3, 2018 · 5:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876343
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OPTION TO PURCHASE COMMON SHARESF2,F1 | $2.06 | Jul 1, 2018 | A | 40,000 | A | — | Jun 30, 2023 | COMMON SHARES | 40,000 | 40,000 | D |
| OPTION TO PURCHASE COMMON SHARESF3 | $3.15 | holding | — | — | — | — | Jun 30, 2022 | COMMON SHARES | 20,000 | 20,000 | D |
| OPTION TO PURCHASE COMMON SHARESF3 | $2.72 | holding | — | — | — | — | Jun 30, 2021 | COMMON SHARES | 20,000 | 20,000 | D |
| OPTION TO PURCHASE COMMON SHARESF3 | $3.57 | holding | — | — | — | — | Jun 30, 2020 | COMMON SHARES | 20,000 | 20,000 | D |
| OPTION TO PURCHASE COMMON SHARESF3 | $3.11 | holding | — | — | — | — | Jun 30, 2019 | COMMON SHARES | 20,000 | 20,000 | D |
Explanation of responses
- F1These options will vest and become exercisable on June 30, 2019, provided, that Neal C. Bradsher remains a member of the issuer's board of directors on that date
- F2The options were granted to Neal Bradsher by the issuer on July 1, 2018 as director compensation pursuant to resolutions from the minutes of the issuer's board of directors meeting on January 24, 2018.
- F3These options are currently exercisable.